A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 12, Issue 4, 2014, Pages

  Alimohamed, Nimira ^a   Lee, Jae Lyn ^b   Srinivas, Sandy ^c   Bjarnason, Georg A ^d   Knox, Jennifer J ^a   Mackenzie, Mary J ^e   Wood, Lori ^f   Vaishampayan, Ulka N ^g   Tan, Min Han ^h   Rha, Sun Young ⁱ   Donskov, Frede ^j   Tantravahi, Srinivas ^k   Kollmannsberger, Christian ^l   North, Scott ^m   Rini, Brian I ⁿ   Choueiri, Toni K ^o   Heng, Daniel Y C ^p  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Asan Medical Center   (South Korea)

^c STANFORD CANCER INSTITUTE   (United States)

^d Sunnybrook Odette Cancer Center   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g WAYNE STATE UNIVERSITY   (United States)

^h INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

ⁱ Yonsei University   (South Korea)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k UNIVERSITY OF UTAH   (United States)

^l BRITISH COLUMBIA CANCER AGENCY   (Canada)

^m CROSS CANCER INSTITUTE   (Canada)

ⁿ TAUSSIG CANCER INSTITUTE   (United States)

^o HARVARD UNIVERSITY   (United States)

^p TOM BAKER CANCER CENTRE   (Canada)

more..

Author keywords

Kidney cancer; Mammalian target of rapamycin; Sequencing; Treatment; Vascular endothelial growth factor

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; BRAIN METASTASIS; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATIENT HISTORY OF NEPHRECTOMY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904723067     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.12.003     Document Type: Article

References (20)

1. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
2. B. Escudier, C. Szczylik, and T.E. Hutson et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
3. C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
4. B.I. Rini, S. Halabi, and J.E. Rosenberg et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
5. B. Escudier, J. Bellmunt, and S. Negrier et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
6. R.J. Motzer, D. Nosov, and T. Eisen et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial J Clin Oncol 30 Suppl 15 2012 (abstract 4501)
7. G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
8. B.I. Rini, B. Escudier, and P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial Lancet 378 2011 1931 1939
9. R.J. Motzer, B. Escudier, and S. Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial Lancet 372 2008 449 456
10. T. Hutson, B. Escudier, and E. Esteban et al. Temsirolimus vs. sorafenib as second-line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial Ann Oncol 23 suppl 9 2012 (Abstract LBA22-PR)
11. M.P. Sablin, S. Negrier, and A. Ravaud et al. Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34
12. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
13. B.I. Rini, G. Wilding, and G. Hudes et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
14. M.J. Mackenzie, B.I. Rini, and P. Elson et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann Oncol 22 2010 145 148
15. I.N. Zama, T.E. Hutson, and P. Elson et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients Cancer 116 2010 5400 5406
16. M.M. Vickers, T.K. Choueiri, and M. Rogers et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor targeted therapy Urology 76 2010 430 434
17. D.Y. Heng, M. MacKenzie, and U.N. Vaishampayan et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy J Clin Oncol 29 Suppl 7 2011 (abstract 305)
18. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
19. T.K. Choueiri, A. Plantade, and P. Elson et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
20. J.P. Dutcher, P. de Souza, and D. McDermott et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies Med Oncol 26 2009 202 209